| Drug Name: | Nuvigil |
| Manufacturer: | Cephalon, Inc. |
| Other Info: | |
| Clinical Trials: | |
NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy and shift work sleep disorder.In OSAHS, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction.
If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL.
If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary.
In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance.
Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness.The effectiveness of NUVIGIL in long term use (greater than 12 weeks) has not been systematically evaluated in placebo controlled trials.
The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient.